<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854123</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2014/02</org_study_id>
    <nct_id>NCT03854123</nct_id>
  </id_info>
  <brief_title>Multiple Sclerosis in the Elderly: Epidemiology, Clinical and MRI Characteristics</brief_title>
  <acronym>OLDMUS</acronym>
  <official_title>Multiple Sclerosis in the Elderly: Epidemiology, Clinical and MRI Characteristics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Observatoire Français de la sclérose en plaques (OFSEP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Little is known about old MS patients. In a previous work, systematic search in Bordeaux,
      Strasbourg and Dijon university hospital regional MS center databases European Database for
      Multiple Sclerosis (EDMUS) retrieved 2% of 75 years old or older Multiple Sclerosis (MS)
      patients in the 3 databases. Data analysis showed that MS may switch off in the very old
      patients with mild progression and very few relapses. The project is to continue this
      preliminary work and extend it with a systematic study of MS in the elderly.

      The scientific aims: To add new insights into long lasting MS natural history in the growing
      population of elderly patients with MS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      75 to 77 years old MS patients whose disease began at 65 years old or earlier will be
      retrieved from the &quot;Observatoire français de la sclérose en plaques&quot; (OFSEP) which includes
      more than 50 000 MS patients in France. Accuracy of these patients' data from 65 to 75 years
      old will be thereafter checked and completed in 3 French MS centers: Lyon, Rennes and
      Bordeaux, participating to this database directly from the patients' clinical files. From
      these 3 MS centers around 150 MS patients from 75 to 77 years old are expected to be analysed
      on site.

      The data wich will be retrieved for these patients are: irreversible disability status scale
      progression, relapses, Magnetic Resonance Imaging (MRI) data, CSF data, Lublin classification
      of type of MS, McDonald 2005 and 2010 criteria, date and age at beginning of progression,
      characteristics and modality of relapses and clinical impairment at the beginning of the
      disease, treatments used, treatment failures and side effects, co morbidity, Barthel index,
      EuroQol-5D (EQ-5D), cognitive impairment (SDMT test), social life data and socio economic
      data. To the investigator's knowledge this will be the first systematic description of very
      old MS patients with data on long term natural history of MS and characteristics in this
      population of elderly MS patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of MS evolution with disability progression (irreversible Disability Status Scale) in 75 to 77 years Old MS Patients from the age of 65 years-old to present time</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>Time to reach the irreversible Kurtzke disability status scale (DSS) score 4, 6 and 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of clinical relapses in 75 years Old or Older MS Patients from the age of 65 years-old to present time</measure>
    <time_frame>At inclusion (day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the clinical characteristics at 75 years Old</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>Clinical conversion to secondary progressive MS date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the Cerebral MRI at 75 years Old</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>Number of lesions on T2 sequence if &lt;9, number of new T2 lesions, Number of Gadolinium enhancing lesions, T1-Hypointense Lesions (T1 Black Holes), MRI Barkhof Criteria and number of periventricular lesions if &lt;3,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the paraclinical characteristics at 75 years Old</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>Distance walked (with or without help)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the paraclinical characteristics at 75 years Old</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>Barthel index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Socio-demographic data</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>sex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Socio-demographic data</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Socio-demographic data</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>department of residence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the treatments at 75 years Old</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>Treatments of multiple sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the treatments at 75 years Old</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>Failures treatments of multiple sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the treatments at 75 years Old</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>Side effects of treatments and other concomitant treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of health-related quality of life at 75 years Old</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>EQ-5D Instruments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of cognitive functions at 75 years Old</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>Symbol digit modalities test (SDMT) test</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Old MS patients</arm_group_label>
    <description>75 to 77 years old MS patients whose disease began at 65 years old or earlier will be retrieved from the &quot;Observatoire français de la sclérose en plaques&quot; (OFSEP).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        75 to 77 years old MS patients whose disease began at 65 years old or earlier will be
        retrieved from the &quot;Observatoire français de la sclérose en plaques&quot; which includes more
        than 50 000 MS patients in France.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with McDonald 2001, 2005 or 2010 criteria of multiple sclerosis 75 to 77
             years old MS patients at the time of inclusion

          -  Patients whose beginning of MS was before 65 years old or 65 years old

          -  Patients who signed OFSEP 's consent

        Exclusion Criteria:

          -  Patients whose clinical data cannot be entered or for whom too much clinical data are
             missing

          -  Alive patients older than 77 years or younger than 75 years the day of the inclusion
             in the study

          -  Patients died before 65 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>77 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe OUALLET, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Bodeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra VUKUSIC, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Observatoire Français de la sclérose en plaques (OFSEP)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Christophe OUALLET, MD, PhD</last_name>
    <phone>(0)556 79 55 21</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-christophe.ouallet@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dieynaba DJIGO</last_name>
    <phone>(0)5 57 57 48 17</phone>
    <phone_ext>+33</phone_ext>
    <email>dieynaba.djigo@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux - Pellegrin - service de neurologie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe OUALLET, MD, PhD</last_name>
      <phone>(0)5 56 79 55 21</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-christophe.ouallet@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Dieynaba DJIGO</last_name>
      <phone>(0)5 57 82 12 75</phone>
      <phone_ext>+33</phone_ext>
      <email>dieynaba.djigo@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Christophe OUALLET, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital neurologique - Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra VUKUSIC, Prof</last_name>
      <email>sandra.vukusic@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Sandra VUKUSIC, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - service de neurologie</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles EDAN, Prof</last_name>
      <email>gilles.edan@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles EDAN, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Geriatric population</keyword>
  <keyword>EDMUS</keyword>
  <keyword>OFSEP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

